Relative to provider contract standards for pharmacy benefit managers.
Impact
The enactment of HB383 is expected to significantly affect the relationship between pharmacies and pharmacy benefit managers. By enforcing stricter contract standards and requiring PBMs to make maximum allowable cost lists accessible, the bill aims to empower pharmacies in negotiating drug prices. This could lead to lower costs for consumers if pharmacies can better navigate pricing structures. Moreover, the bill is likely to align state laws with emerging trends in pharmacy management that prioritize consumer access to affordable medications.
Summary
House Bill 383 aims to set new standards for provider contracts associated with pharmacy benefit managers (PBMs) in New Hampshire. The legislation introduces amendments to existing regulations, specifically targeting transparency and accountability in drug pricing. It requires PBMs to disclose information about national drug codes and the sources of drug products that can be purchased at or below the maximum allowable cost. Additionally, it mandates that PBMs inform all pharmacies about the dates when claims can be reprocessed based on pricing changes, enhancing operational transparency.
Contention
During discussions surrounding HB383, concerns were raised about the regulatory burden imposed on PBMs and whether the requirements could lead to increased operational costs that may ultimately affect drug prices. Stakeholders in the healthcare industry expressed differing opinions: supporters argued that more rigorous standards would protect consumers and enhance competition among pharmacies, while opponents feared that the new regulations could lead to unintended consequences, including higher administrative costs and potential disruptions in service delivery.